CL2021001046A1 - Composiciones farmacéuticas mucoadhesivas de corticoesteroides - Google Patents

Composiciones farmacéuticas mucoadhesivas de corticoesteroides

Info

Publication number
CL2021001046A1
CL2021001046A1 CL2021001046A CL2021001046A CL2021001046A1 CL 2021001046 A1 CL2021001046 A1 CL 2021001046A1 CL 2021001046 A CL2021001046 A CL 2021001046A CL 2021001046 A CL2021001046 A CL 2021001046A CL 2021001046 A1 CL2021001046 A1 CL 2021001046A1
Authority
CL
Chile
Prior art keywords
mucoadhesive
pharmaceutical compositions
corticosteroid
compositions
corticosteroid pharmaceutical
Prior art date
Application number
CL2021001046A
Other languages
English (en)
Inventor
Arnaud Grenier
Dario Carrara
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2021001046A1 publication Critical patent/CL2021001046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen composiciones farmacéuticas mucoadhesivas de corticoesteroides, así como métodos para preparar tales composiciones farmacéuticas y métodos terapéuticos que las usan. Las composiciones normalmente comprenden un corticoesteroide en un sistema mucoadhesivo, en donde el sistema mucoadhesivo comprende un agente modificador de la reología y un vehículo para el corticoesteroide. Las composiciones son particularmente útiles para el tratamiento de afecciones inflamatorias del esófago tales como esofagitis eosinofílica o enfermedad intestinal inflamatoria.
CL2021001046A 2018-10-24 2021-04-23 Composiciones farmacéuticas mucoadhesivas de corticoesteroides CL2021001046A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862749878P 2018-10-24 2018-10-24
EP19150077 2019-01-02

Publications (1)

Publication Number Publication Date
CL2021001046A1 true CL2021001046A1 (es) 2022-01-07

Family

ID=68296606

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001046A CL2021001046A1 (es) 2018-10-24 2021-04-23 Composiciones farmacéuticas mucoadhesivas de corticoesteroides

Country Status (16)

Country Link
US (1) US20210379081A1 (es)
EP (2) EP4233872A3 (es)
JP (1) JP7479362B2 (es)
KR (1) KR20210088547A (es)
CN (1) CN113271979A (es)
AU (1) AU2019365253A1 (es)
BR (1) BR112021007140A2 (es)
CA (1) CA3116649A1 (es)
CL (1) CL2021001046A1 (es)
CO (1) CO2021005913A2 (es)
DK (1) DK3870226T3 (es)
ES (1) ES2956849T3 (es)
FI (1) FI3870226T3 (es)
MX (1) MX2021004537A (es)
PL (1) PL3870226T3 (es)
WO (1) WO2020084530A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386422A1 (en) * 1999-10-22 2001-04-26 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
KR20050007585A (ko) 2001-06-07 2005-01-19 치오우 컨설팅, 인코포레이티드 아프타 궤양 및 단순 헤르페스 병변의 예방 및 치료조성물 및 방법
US20030059446A1 (en) 2001-09-18 2003-03-27 Kulkarni Arun B. Physically stable sprayable gel composition
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
AU2003265624B2 (en) 2003-08-21 2011-03-31 Abeona Therapeutics Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CN101939024A (zh) * 2007-11-13 2011-01-05 梅里蒂奇制药公司 用于治疗胃肠炎的组合物
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
ES2622372T3 (es) 2012-11-09 2017-07-06 Scidose Llc Composición de enema para tratamiento de la colitis ulcerosa que tiene estabilidad a largo plazo
NZ725028A (en) 2014-05-01 2019-01-25 Integral Biosystems Llc Membrane-adherent self-assembled systems for treatment of ocular disorders
EP3659607A1 (en) 2015-05-04 2020-06-03 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Also Published As

Publication number Publication date
JP7479362B2 (ja) 2024-05-08
EP4233872A2 (en) 2023-08-30
PL3870226T3 (pl) 2023-12-27
BR112021007140A2 (pt) 2021-07-20
DK3870226T3 (da) 2023-09-18
US20210379081A1 (en) 2021-12-09
JP2022505535A (ja) 2022-01-14
AU2019365253A1 (en) 2021-05-27
WO2020084530A1 (en) 2020-04-30
EP3870226B1 (en) 2023-06-28
ES2956849T3 (es) 2023-12-29
CO2021005913A2 (es) 2021-05-20
EP3870226A1 (en) 2021-09-01
CN113271979A (zh) 2021-08-17
FI3870226T3 (fi) 2023-09-15
MX2021004537A (es) 2021-06-15
EP4233872A3 (en) 2023-10-11
KR20210088547A (ko) 2021-07-14
CA3116649A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
UY37464A (es) Métodos para tratar infecciones por el virus filoviridae
CO2018005327A2 (es) Profármacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20190394A (es) Compuestos de inhibidores de autotaxina
PH12019500946A1 (en) Neutralizing anti-tl1a monoclonal antibodies
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CO6680695A2 (es) Formulaciones farmacéuticas que contienen rifaximina procesos para su obtención y método para tratar enfermedad intestinal
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6